Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.

Por Evans, W. K., Will, B. P., Berthelot, J. M., Wolfson, M. C.
Publicado em 1995

Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration

Por Evans, W.K., Flanagan, W.M., Miller, A.B., Goffin, J.R., Memon, S., Fitzgerald, N., Wolfson, M.C.
Publicado no Curr Oncol (2016)

First do no harm: extending the debate on the provision of preventive tamoxifen

Por Will, B P, Nobrega, K M, Berthelot, J-M, Flanagan, W, Wolfson, M C, Logan, D M, Evans, W K
Publicado em 2001

Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening...

Por Popadiuk, C., Gauvreau, C.L., Bhavsar, M., Nadeau, C., Asakawa, K., Flanagan, W.M., Wolfson, M.C., Coldman, A.J., Memon, S., Fitzgerald, N., Lacombe, J., Miller, A.B.
Publicado no Curr Oncol (2016)